Interhospital variability in health care–associated infections and payments after durable ventricular assist device implant among Medicare beneficiaries

Donald S. Likosky,Guangyu Yang,Min Zhang,Preeti N. Malani,Michael D. Fetters,Raymond J. Strobel,Carol E. Chenoweth,Hechuan Hou,Francis D. Pagani,Michigan Congestive Heart Failure Investigators,Donald S. Likosky,Francis D. Pagani,Ashraf Shaaban Abdel Aziz Abou El Ela,Paul C. Tang,Michael P. Thompson,Keith Aaronson,Supriya Shore,Thomas Cascino,Katherine B. Salciccioli,Min Zhang,Jeffrey S. McCullough,Michelle Hou,Allison M. Janda,Michael R. Mathis,Tessa M.F. Watt,Michael J. Pienta,Alexander Brescia,Austin Airhart,Daniel Liesman,Khalil Nassar

DOI: https://doi.org/10.1016/j.jtcvs.2021.04.074

2021-05-01

Abstract:<h2 class="section-title u-h3 u-margin-l-top u-margin-xs-bottom">STRUCTURED </h2><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Objective</h3><p>To investigate variations across hospitals in infection rates and associated costs, the latter reflected in 90-day Medicare payments. Despite high rates and expenditures of healthcare-associated infections associated with durable ventricular assist device implant, few studies have examined inter-hospital variation and associated costs.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>Clinical data on 8,688 patients receiving primary durable ventricular assist devices from July 2008 to July 2017 from The Society of Thoracic Surgeons Interagency Registry for Mechanically Assisted Circulatory Support ("Intermacs") hospitals (n=120) were merged with post-implant 90-day Medicare claims. Terciles of hospital-specific, risk-adjusted infection rates per 100 patient-months were estimated using Intermacs and associated with Medicare payments (among 5,440 Medicare beneficiaries). Primary outcomes included infections within 90 days of implant and Medicare payments.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>There were 3,982 infections identified among 27.8% (2,417/8,688) of patients developing an infection. The median (25^th, 75^th percentile) adjusted incidence of infections (per 100 patient-months) across hospitals was 14.3 (9.3, 19.5) and varied by hospital (range 0.0 – 35.6). Total Medicare payments from implant to 90-days were 9.0% (absolute difference: $13,652) greater in high versus low infection tercile hospitals, p&lt;0.0001. The period between implant to discharge accounted for 73.1% of the difference in payments during the implant to 90-day period across terciles.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>Healthcare-associated infection rates post-durable ventricular assist device implant varied by hospital and were associated with increased 90-day Medicare expenditures. Interventions targeting preventing infections could improve the value of durable ventricular assist device support from both the societal and hospital perspectives.</p>

surgery,cardiac & cardiovascular systems,respiratory system

What problem does this paper attempt to address?

This paper aims to explore the differences in the incidence of healthcare - associated infections (HAIs) and cost payments among different hospitals after the implantation of durable ventricular assist devices (VAD). Specifically, the study focuses on whether there are significant differences in the incidence of HAIs among different hospitals among Medicare beneficiaries after VAD implantation surgery, and how these differences affect medical cost payments.

### Research Background
- **Problem Definition**: Healthcare - associated infections (HAIs) are one of the common complications after VAD implantation, which not only pose a threat to patients' health but also increase medical costs. Different hospitals may have differences in managing HAIs, and these differences may lead to different patient outcomes and medical costs.
- **Research Purpose**: By analyzing the incidence of HAIs and cost payments among different hospitals, identify the factors that may cause these differences, and provide a basis for improving patient management and reducing medical costs.

### Main Research Contents
1. **Data Sources**: The study used information from Medicare claims data and the The Society of Thoracic Surgeons (STS) Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) database.
2. **Research Methods**:
- **HAIs Modeling**: A proportional rate model was used to model the occurrence of HAIs, adjusting for patients' preoperative risk factors and stratifying the influence of different hospitals.
- **Cost Payment Analysis**: Analyzed the hospitalization costs, doctor fees, and other medical service costs (such as outpatient services, drug costs, long - term care services, etc.) after VAD implantation, and carried out price standardization and inflation adjustment.
3. **Result Evaluation**: By comparing the incidence of HAIs and cost payments among different hospitals, evaluate the variability among hospitals and potential influencing factors.

### Key Issues
- **Differences in the Incidence of HAIs**: The study found that there are significant differences in the incidence of HAIs among different hospitals. Hospitals with a high incidence of HAIs may need more medical resources to deal with these infections.
- **Differences in Cost Payments**: Hospitals with a higher incidence of HAIs also have relatively higher medical cost payments, indicating that HAIs not only affect patients' health but also increase the economic burden on the medical system.

### Conclusion
This study reveals significant differences among different hospitals in managing HAIs after VAD implantation, and emphasizes the importance of optimizing infection control measures and improving medical quality. By reducing the occurrence of HAIs, not only can the prognosis of patients be improved, but also medical costs can be effectively reduced.

Hope this information is helpful for you to understand the research purpose of this paper. If you have any further questions or need more detailed information, please feel free to let us know.